IFNA1 and coronary artery disorder: The latest European guidelines consider the use of Peg-IFNα in all patients with CHD and compensated liver disease and prefer a 48 week regimen considering the patient’s clinical condition, treatment tolerance and virologic response through HDV RNA and HBsAg (European Association for the Study of the Liver, 2023).